Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A clinical trial of a potential Ebola therapy, led by Oxford University, has got under way in Sierra Leone.

The phase II study of the treatment, called TKM-Ebola-Guinea, led by Oxford's Professor Peter Horby on behalf of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), is funded through the Wellcome Trust's £3.2 million Ebola therapeutics platform.

Read more

Book tickets to hear Professor Adrian Hill speak on vaccines for Ebola and Malaria – Thursday 23 April at 6pm

Similar stories

No limit to the benefits of exercise in reducing the risk of cardiovascular disease

General Research

A new study led by the University of Oxford on over 90,000 participants shows that there is no upper threshold to the benefits of exercise in reducing the risk of cardiovascular disease – ‘every move counts towards better cardiovascular health.’

Accurate predictions of ovarian cancer outcome possible with new classification system

General Research

The new, Oxford-developed method for subtyping ovarian cancer has been validated in a recent collaboration between the University of Oxford and Imperial College London. Dubbed the ‘Oxford Classic’, researchers have demonstrated that it enables the accurate prediction of patient disease outcome, as well as the development of new targeted cancer therapies.

Accidental awareness in obstetric surgery under general anaesthesia more frequent than expected

General Research

The largest ever study of awareness during obstetric general anaesthesia shows around 1 in 250 women may be affected, and some may experience long-term psychological harm.